How Cloud to Edge Technology Helps Handle the Immense Amount of Data Generated By Practitioners

 

Healthcare organizations generate massive amounts of data, so much so that the challenge becomes how and where to move it and store it.

Health and Life Science at the Edge host, Gabrielle Bejarano, spoke with Zettar’s Chin Fang and Intel’s Michael McManus for a peek inside the technology solutions Zettar and Intel are partnering on to advance the challenge of data movement, processing, and storage for healthcare organizations.

Genomics files are a perfect example of the type of sizable data files that life science companies are creating. “When you go to genomics, for example, genomics files, a whole genome for a single person is about 350 gigabytes,” McManus says. “So, if you’re sequencing many people, you multiply however many people, you’re sequencing times 350 gigabytes for your storage planning purpose.” And he says cryoelectronic microscopy data sets are multiple terabytes in sizes. The data is broken into single gigabyte movies, and the average microscope can create thousands of those an hour. And then, the data requires analysis.

Chin adds there are some institutions Zettar works with whose processes generate files as big as four terabytes with rates of one terabyte per second that requires aggressive data reduction to reduce that to the gross rate of 800 Gbps, or 100 gigabytes per second.

These huge datasets cause a myriad of problems for technicians, scientists, and IT staff, including wasted time, frustration, and a loss of productivity.

Standard data-moving practices can’t handle these complex situations, so Zettar’s approach utilizes an efficient unified data-mover model. “With Intel’s help, we developed this real-time capability, so now we make the real-time data movement readily available to anyone who needs it, and then this will have great benefits to accelerate the healthcare and life sciences research efforts going forward,” Chin says.

Learn more about Health and Life Science data movement solutions by connecting with Chin Fang and Michael McManus on LinkedIn or visit Intel Health and Life Sciences.  

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Health and Life Sciences at the Edge.

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More